Year: 2023

First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal Phase 3 SEACRAFT-2 trial initiation in NRAS-mutated melanoma on track for H1 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or...

CALGARY, Alberta, Dec. 11, 2023 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX: DRT; OTC: DRTTF), a leader in industrialized construction, announced today that it has filed an amended and restated rights offering notice and an amended and restated rights offering circular (collectively, the “Amended Documents“) in connection with the previously announced rights offering to its common shareholders for aggregate gross proceeds of C$30,000,000 (the “Rights Offering”). Pursuant to the terms of a standby purchase agreement dated November 20, 2023, two of DIRTT’s significant shareholders (the “Standby Purchasers“) have agreed to provide a standby commitment to fully backstop the Rights Offering. DIRTT has filed the Amended Documents to update the Standby Purchasers’...

TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, today announced topline results from the Ersa Phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites. In this study, TP-03 demonstrated statistically significant and clinically meaningful improvements compared to baseline in two objective measures of the disease...

Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced a new research collaboration with a large pharmaceutical company for its BioJet™ Systemic Oral Delivery Platform. The new agreement provides funding to test the BioJet platform’s ability to achieve bioavailability through oral delivery of the undisclosed collaborator’s molecules to the small intestine in animal models. “This most recent deal shows that we are making great progress, and that progress is being recognized by others,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We’re currently progressing two of our research collaboration studies...

CUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on December 14th, 2023. Dr. Bhat will engage in a “CEO Chat” session with John Vandermosten, Senior Biotechnology Analyst with Zacks Small-Cap Research. The Life Sciences Investor Forum   Date: Thursday, December 14, 2023   Time: 12 p.m. ET  Location: Virtual  Link: Click Here  Available for 1×1 meetings: Thursday, December 14,...

Emphasizing Expected Long-Term Financial Outlook and Strong Cash Flow Generation in 2024 and Beyond Identifies Significant Cost Savings for Immediate Positive Impact on Free Cash Flow BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) —  Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a leading global provider of personal cloud software and services, today provided the following updates enabled by the completion of its cloud-only transformation. In November, the Company announced the divestiture of its Messaging and NetworkX operations in conjunction with its Cloud-only business transformation. Post-transaction, management shared its initial expectation to improve the Company cost profile by eliminating approximately $10 million to $15 million of stranded and other costs from the standalone Cloud...

Live Presentation on December 14, 2023, at 11:00 am ET SALT LAKE CITY, Dec. 11, 2023 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes, today announced that Steve Fife, CEO, and Carl Aure, CFO, will be participating in the Water Tower Research Fireside Chat Series on Thursday, December 14, 2023, at 11:00 am ET. This event is open access for all investors to participate. Topics may include:LifeVantage’s strategy of activating financial, social, and community wellness through its proprietary product portfolio and its connected network of independent consultants. The recent implementation of its LV360 initiatives, including the new Evolve compensation plan for its consultants. New product activity, including the widely successful...

SRIVARU provides affordable premium electric two-wheeled vehicles that provide an exceptional riding experienceSRIVARU becomes the first India-based, U.S.-listed electric motorcycle companyFormer Tesla Executive, Mohanraj Ramasamy, assumes role as CEO of the combined companies Poised to capture a significant share of the multi-billion-dollar Indian and global EV markets based on surging demand, state-of-the-art technologies and capital-efficient business model Expected to commence trading on Nasdaq under new ticker symbol “SVMH” effective today, December 11, 2023. Delaware, USA and Coimbatore, India, Dec. 11, 2023 (GLOBE NEWSWIRE) — SRIVARU Holding Limited (Nasdaq: SVMH; SVMHW, MOBVU, MOBV, MOBVW) (“SRIVARU” or the “Company”), a commercial-stage provider of premium electric motorcycles, today provided a business update...

COLUMBIA, Md., Dec. 11, 2023 (GLOBE NEWSWIRE) — BigBear.ai (NYSE: BBAI), a premier provider of artificial intelligence (AI)-enabled business intelligence solutions, today announces it is working with Amazon Web Services (AWS) Professional Services (ProServe). By working with AWS, BigBear.ai reinforces its position as a leader in AI-driven solutions. AWS ProServe customers will be able to access the power of BigBear’s ProModel AI-driven warehousing solutions, including optimized facilities design, streamlined process workflows, efficient staffing models, arrival and departure scheduling, and strategic resource allocation, among other enhancements. ProModel is BigBear.ai’s renowned discrete-event simulation (DES) product that establishes new standards in digital twin solutions for supply chain and warehouse solutions. “This...